# Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

> **NCT03713944** · PHASE2 · TERMINATED · sponsor: **Nasser Hanna** · enrollment: 30 (actual)

## Conditions studied

- NSCLC Stage IV
- NSCLC, Recurrent

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03713944
- **Lead sponsor:** Nasser Hanna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-15
- **Primary completion:** 2021-12-16
- **Final completion:** 2021-12-16
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Extreme toxicity, thromboembolic events
- **Last updated:** 2023-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03713944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03713944, "Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03713944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*